Navitas Life Sciences

Adaptive design for a global Study for a First-in-Class Therapy for Critical Covid-19 Patient

Navitas Life Sciences provided end-to-end support to a US Based mid-size biotech company in the development of their first in class therapy for critically ill covid patients. The Phase I study had been conducted in the US, and the company needed a partner to conduct the Phase II study in multiple countries - USA, India and other potential countries.

Navitas Life Sciences’ experienced Medical writers, Medical Leads and Biostatistics teams collaborated to deliver a well designed innovative and adaptive, two stage study protocol within a short span.

Download this Case Study to Learn how we:

  • Developed a robust study protocol
  • Completed the study in a short span
  • Received Appreciation from the USFDA

Please complete the form to download our Case Study.

Please complete form to download PDF
First Name
Last Name
Business Email
Job Title
By submitting this form, I agree to receive email communications from Navitas Life Sciences. Privacy Policy

© 2022 Navitas Life Sciences | Privacy Policy